Header Logo

Connection

ANDREW YEE to Immunoconjugates

Back to Details
This is a "connection" page, showing publications ANDREW YEE has written about Immunoconjugates.
ANDREW YEE
Connection Strength
0.222
Immunoconjugates
  1. Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma. Leuk Lymphoma. 2024 Dec; 65(12):1789-1800.
    View in: PubMed
    Score: 0.222
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.